Telehealth company Hims & Hers announced it will stop offering a compounded version of Novo Nordisk’s Wegovy after escalating legal threats and regulatory scrutiny from U.S. authorities. Novo Nordisk and federal regulators signaled the product was an unapproved rendition of a branded GLP‑1, prompting Hims to withdraw access days after launching the offering. The pullback follows warnings from regulators about mass compounding of approved drugs and reports that U.S. agencies are considering enforcement action. The dispute has drawn industry attention because it touches on intellectual property, compounding liability, and access to high-demand weight‑loss medicines. Compounded drugs are customized formulations made by pharmacies and are not reviewed by the FDA the way branded products are; regulators argue large‑scale compounding of an approved drug risks patient safety and undermines innovation incentives. Companies, payors, and policy makers are now watching for potential DOJ or FDA actions that could set precedents for telehealth‑driven drug distribution.